Structure Therapeutics Inc. Basic Shares Outstanding (Weighted Average)
Structure Therapeutics Inc. (GPCR) reported Basic Shares Outstanding (Weighted Average) of 217.96 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-06
- Structure Therapeutics Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 217.96M shares, a 26.24% increase year-over-year.
- Structure Therapeutics Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 217.33M shares, a 26.31% increase year-over-year.
- Structure Therapeutics Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 190.18M shares, a 10.63% increase year-over-year.
- Structure Therapeutics Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 175.47M shares, a 2.24% increase year-over-year.
- Structure Therapeutics Inc. weighted average number of shares outstanding, basic for fiscal 2025 was 177.60M shares, a 12.46% increase from fiscal 2024.
- Structure Therapeutics Inc. weighted average number of shares outstanding, basic for fiscal 2024 was 157.92M shares, a 43.31% increase from fiscal 2023.
- Structure Therapeutics Inc. weighted average number of shares outstanding, basic for fiscal 2023 was 110.20M shares, a 1049.81% increase from fiscal 2022.
- Structure Therapeutics Inc. weighted average number of shares outstanding, basic for fiscal 2022 was 9.58M shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 217.96M shares 10-Q · filed 2026-08-06 | 217.64M shares 10-Q · filed 2026-08-06 | 208.49M shares derived: average of 3 quarters · filed 2026-08-06 | 200.23M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 217.33M shares 10-Q · filed 2026-05-07 | 203.75M shares derived: average of 2 quarters · filed 2026-05-07 | 194.32M shares derived: average of 3 quarters · filed 2026-05-07 | 188.91M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | 190.18M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 182.82M shares derived: average of 2 quarters · filed 2026-02-26 | 179.43M shares derived: average of 3 quarters · filed 2026-08-06 | 177.60M shares 10-K · filed 2026-02-26 |
| 2025-09-30 | 175.47M shares 10-Q · filed 2025-11-06 | 174.06M shares derived: average of 2 quarters · filed 2026-08-06 | 173.40M shares 10-Q · filed 2025-11-06 | 173.02M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | 172.65M shares 10-Q · filed 2026-08-06 | 172.35M shares 10-Q · filed 2026-08-06 | 172.20M shares derived: average of 3 quarters · filed 2026-08-06 | 172.06M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | 172.05M shares 10-Q · filed 2026-05-07 | 171.98M shares derived: average of 2 quarters · filed 2026-05-07 | 171.86M shares derived: average of 3 quarters · filed 2026-05-07 | 165.96M shares derived: average of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | 171.91M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 171.77M shares derived: average of 2 quarters · filed 2026-02-26 | 163.93M shares derived: average of 3 quarters · filed 2026-02-26 | 157.92M shares 10-K · filed 2026-02-26 |
| 2024-09-30 | 171.63M shares 10-Q · filed 2025-11-06 | 159.93M shares derived: average of 2 quarters · filed 2025-11-06 | 153.26M shares 10-Q · filed 2025-11-06 | 149.63M shares derived: average of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | 148.24M shares 10-Q · filed 2025-08-06 | 143.97M shares 10-Q · filed 2025-08-06 | 142.30M shares derived: average of 3 quarters · filed 2026-02-26 | 135.46M shares derived: average of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | 139.71M shares 10-Q · filed 2025-05-08 | 139.33M shares derived: average of 2 quarters · filed 2026-02-26 | 131.20M shares derived: average of 3 quarters · filed 2026-02-26 | 127.09M shares derived: average of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | 138.95M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 126.95M shares derived: average of 2 quarters · filed 2026-02-26 | 122.89M shares derived: average of 3 quarters · filed 2026-02-26 | 110.20M shares 10-K · filed 2026-02-26 |
| 2023-09-30 | 114.95M shares 10-Q · filed 2024-11-13 | 114.85M shares derived: average of 2 quarters · filed 2024-11-13 | 100.61M shares 10-Q · filed 2024-11-13 | 77.85M shares derived: average of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | 114.76M shares 10-Q · filed 2024-08-08 | 93.33M shares 10-Q · filed 2024-08-08 | 65.49M shares derived: average of 3 quarters · filed 2024-08-08 | 51.56M shares derived: average of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | 71.66M shares 10-Q · filed 2024-05-09 | 40.85M shares derived: average of 2 quarters · filed 2024-05-09 | 30.50M shares derived: average of 3 quarters · filed 2024-05-09 | 25.23M shares derived: average of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | 10.05M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | 9.92M shares derived: average of 2 quarters · filed 2024-03-08 | 9.76M shares derived: average of 3 quarters · filed 2024-03-08 | 9.58M shares 10-K · filed 2024-03-08 |
| 2022-09-30 | 9.78M shares 10-Q · filed 2023-11-17 | 9.61M shares derived: average of 2 quarters · filed 2023-11-17 | 9.43M shares 10-Q · filed 2023-11-17 | |
| 2022-06-30 | 9.44M shares 10-Q/A · filed 2023-11-17 | 9.25M shares 10-Q/A · filed 2023-11-17 | ||
| 2022-03-31 | 9.06M shares 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |